# Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

> **NCT06122584** · PHASE3 · RECRUITING · sponsor: **ABX advanced biochemical compounds GmbH** · enrollment: 380 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** [18F]PSMA-1007

## Key facts

- **NCT ID:** NCT06122584
- **Lead sponsor:** ABX advanced biochemical compounds GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-13
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06122584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06122584, "Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06122584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*